Susquehanna analyst James Friedman maintains EPAM Sys (NYSE:EPAM) with a Positive and lowers the price target from $496 to $475.
HC Wainwright & Co. Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $18 to $7.